Fenwick Represents Recludix Pharma in Equity Financing

Fenwick represented Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, in its equity financing. The round was led by Access Biotechnology, Alexandria Venture Investments, NEA, and Westlake BioPartners, with a strategic investment by Eli Lilly and Company.

Recludix Pharma will use the funds to support the swift generation of clinical data from its pipeline of novel, first-in-class SH2 domain inhibitors, and expand its artificial intelligence and machine learning resources with Lilly TuneLab to expedite development of its next generation of small molecule therapies using its proprietary platform. More information can be obtained from the company announcement.

The Fenwick transaction team was led by corporate partners Effie Toshav and Fei Xu and included associates Adam Conway, Sarah Marshall, and Patrick Paulsen.